EXN-407 is under clinical development by Exonate and currently in Phase II for Diabetic Retinopathy. According to GlobalData, Phase II drugs for Diabetic Retinopathy have a 53% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how EXN-407’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EXN-407 overview
EXN-407 is under development for the treatment of wet macular degeneration, diabetic macular edema and diabetic retinopathy. The therapeutic candidate is administered through ophthalmic route as eye drops. It is piperazine derivative. It act by targeting serine/threonine-protein kinase (SRPK1).
Exonate overview
Exonate is a biopharmaceutical company based in the UK. It is engaged in the discovery and development of small-molecule drugs that modulate alternative mRNA splicing. The company develops small-molecule drugs to address diseases with high unmet medical requirements. Exonate is focused on developing a minimally invasive therapy, by delivery as an eye drop rather than as an injection, to prevent vision loss in patients with Diabetic Macular Odema (DMO) and Wet Age-Related Macular Degeneration (wAMD). The company aims to specifically target the pathological blood vessel growth that underlies the progression to blindness by reducing the angiogenic VEGF isoforms. Exonate is headquartered in Duxford, Cambridgeshire, United Kingdom.
For a complete picture of EXN-407’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
